Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
1.56% $18.24
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 698.34 mill |
EPS: | -1.570 |
P/E: | -11.62 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 93.11 mill |
Avg Daily Volume: | 1.045 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -11.62 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.98x |
Company: PE -11.62 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.266 (-93.06%) $-16.97 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 17.22 - 19.22 ( +/- 5.50%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-07 | Moore John R | Sell | 17 993 | Stock Option (Right to Buy) |
2024-02-08 | Moore John R | Sell | 3 813 | Stock Option (Right to Buy) |
2024-02-09 | Moore John R | Sell | 8 029 | Stock Option (Right to Buy) |
2024-02-07 | Moore John R | Buy | 17 993 | Common Stock |
2024-02-09 | Moore John R | Buy | 8 029 | Common Stock |
INSIDER POWER |
---|
74.97 |
Last 97 transactions |
Buy: 6 997 164 | Sell: 659 479 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $18.24 (1.56% ) |
Volume | 0.462 mill |
Avg. Vol. | 1.045 mill |
% of Avg. Vol | 44.20 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $19.98 | N/A | Active |
---|
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.